Similar low rates of virologic failure and safety endpoints seen in both arms.
Inflammatory marker levels at baseline associated with increases in peripheral fat and lean body mass, but not central adiposity.
Over 5 years of exposure, the risk of developing CKD increased > 300-fold with atazanavir/ritonavir, > 200-fold with lopinavir/ritonavir, and 174-fold with tenofovir DF compared with no exposure to each agent.
Improved safety profile likely attributable to 90% lower plasma tenofovir levels in patients receiving EVG/COBI/FTC/TAF vs EVG/COBI/FTC/TDF.
In multivariate analysis, no impact of previous treatment experience, cirrhosis status or ARV regimen on SVR; all 10 patients with relapse were black.
Good adherence to event-driven dosing regimen delivered before and after sex without evidence of risk compensation
Treatment-naive patients who received oral cabotegravir-based induction and maintenance therapy experienced numerically lower rates of discontinuation for AEs and had comparable virologic suppression rates compared with patients treated with efavirenz-based therapy through 96 weeks.
The increased risk of MI identified in individuals who received abacavir was diminished after adjusting for cardiovascular and HIV-associated risk factors.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.